Skip to main content

Table 4 Concordance of NCCN-recommended molecular targets detected by both FoundationACT and FoundationOne assays in 42 patients with advanced solid tumors

From: Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors

Tumor types Genomic alterations No. concordance (N = 22) No. unique to FoundationOne (N = 4) % concordance (N = 26) No. unique to FoundationACT (N = 8)
NSCLC (N = 33) EGFR L858R and exon 19 deletions 8 2 80% 0
EGFR T790 M 2 1 67% 0
ALK rearrangements 4 0 100% 0
BRAF V600 mutation 1 0 100% 0
MET exon 14 skip site alterations 2 1 67% 0
ERBB2 mutations 0 0 100% 2
Breast (N = 7) ERBB2 amplification or mutation 1 0 100% 1
BRCA1/2 mutations 2 0 100% 4
Ovarian (N = 2) BRCA1/2 mutations 2 0 100% 0
  1. NCCN National Comprehensive Cancer Network, NSCLC non-small-cell lung carcinoma